Skip to main content

Programmable ARTificial immune systems to fight cancer

Project description

Cancer immunotherapy finds its niche

Activating an immune response to harmful pathogens requires the interaction of several types of immune cells. Specialised 'niches' found in lymph organs, inflammation sites and tumour microenvironments are the sites of this activity. ARTimmune is engineering very powerful synthetic immune niches to enhance cancer immunotherapy. Scientists will increase understanding of cellular interactions in lymph nodes, leading to the targeted design of powerful immunomodulating molecules. Then, like commandos with powerful weapons dropped into a target, the molecules will be injected into the lymph nodes along with a scaffold that encourages immune cell infiltration. Locally enhancing immune activity could prove more effective with far fewer side effects than conventional systemic immunotherapy, changing the prognoses for millions of cancer patients.

Host institution

STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM
Net EU contribution
€ 2 500 000,00
Address
Geert Grooteplein 10 Zuid
6525 GA Nijmegen
Netherlands

See on map

Region
Oost-Nederland Gelderland Arnhem/Nijmegen
Activity type
Higher or Secondary Education Establishments
Non-EU contribution
€ 0,00

Beneficiaries (2)

STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM
Netherlands
Net EU contribution
€ 2 500 000,00
Address
Geert Grooteplein 10 Zuid
6525 GA Nijmegen

See on map

Region
Oost-Nederland Gelderland Arnhem/Nijmegen
Activity type
Higher or Secondary Education Establishments
Non-EU contribution
€ 0,00
STICHTING RADBOUD UNIVERSITEIT

Participation ended

Netherlands
Net EU contribution
€ 0,00
Address
Houtlaan 4
6525 XZ Nijmegen

See on map

Region
Oost-Nederland Gelderland Arnhem/Nijmegen
Activity type
Higher or Secondary Education Establishments
Non-EU contribution
€ 0,00